Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people have been diagnosed with (1) Chrohn's and (2) Colitis in (a) South Holland and the Deepings and (b) Lincolnshire in each of the last five years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Neither the Department nor NHS England hold data on the total number of people diagnosed with Crohn’s disease or colitis in South Holland and the Deepings or Lincolnshire in each of the last five years. However, the following table shows a count hospital admissions (FAEs) where there was a primary diagnosis Crohn's disease or colitis and where the patient was resident in Lincolnshire or South Holland and the Deepings, each year from 2020/21 to 2024/25:
Year | South Holland and Deepings | Lincolnshire | ||
Crohn’s | Colitis | Crohn’s | Colitis | |
2020/21 | 125 | 305 | 2,350 | 3,355 |
2021/22 | 175 | 410 | 2,765 | 4,295 |
2022/23 | 180 | 480 | 3,130 | 4,890 |
2023/24 | 165 | 465 | 3,390 | 5,275 |
2024/25 | 75 | 190 | 3,675 | 6,455 |
Source: Hospital Episode Statistics, published by NHS England
Notes:
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many removals from elective waiting lists there have been as a result of data validation exercises in 2025-26; and what the cost to his Department has been of those exercises.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Validation is a well-established component for the effective management of waiting lists, ensuring that the patients who are on the list should still be there. While we have significantly reduced the size of the total elective waiting list by over 206,000 since the Government took office, a large list requires consistent validation in order to ensure that all patients on the list still require care, and all appointments are of optimum value for patients and clinicians.
The Department does not hold data centrally on the number of patient pathways removed from the elective waiting list as a result of data validation.
NHS England has paid the system £18,818,566 for validation exercises from April to September 2025. Payments for the most recent validation exercises have not yet been issued to providers. We know validation provides significant benefits for patients by reducing missed appointments, making effective use of clinical time, and ensuring patients are on the best care pathway for their needs.
Asked by: Stella Creasy (Labour (Co-op) - Walthamstow)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of the restriction on pursuing clinical negligence cases to direct financial dependents only in cases where an individual has died on the justice system.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Freddie van Mierlo (Liberal Democrat - Henley and Thame)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support for training and resources his Department is providing to integrated care boards to help implement the NHS England Maternal Care Bundle, published on 6 January 2026.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the average length of time of a GP appointment.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Freddie van Mierlo (Liberal Democrat - Henley and Thame)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he is taking steps to ensure that all patients with suspected leukaemia symptoms can access a full blood count test within 48 hours, as recommended by the NICE NG12 guidelines.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is determined to take all the necessary steps to improve early diagnosis for all cancers, including blood cancers such as leukaemia.
To accomplish this, the National Health Service is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways.
The National Institute for Health and Care Excellence (NICE) has a guideline on suspected cancer called ‘recognition and referral’ which aim to support the identification of children, young people and adults with symptoms that could be caused by cancer’. The guideline provides guidance on appropriate investigations in primary care, and the selection of people to refer for a specialist opinion. The guideline recommends that people with specific symptoms should be offered a very urgent full blood count to assess for leukaemia. Local NHS organisations are expected to take NICE guidelines fully into account in ensuring that their services meet the needs of their local populations. The NHS is held to account to deliver guidelines, which include all NICE directions, at local and regional level.
The National Cancer Plan for England will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care, as well as prevention. The plan will seek to improve every aspect of cancer care to better the experience and outcomes for all patient groups, including leukaemia patients.
Asked by: Baroness Bennett of Manor Castle (Green Party - Life peer)
Question to the Department for Environment, Food and Rural Affairs:
To ask His Majesty's Government, with regard to the independent report Chief Medical Officer’s annual report 2025: infections, published on 4 December 2025, what action they plan to take in response to the specific additional recommendation about the link between agricultural use of novel fungicides and the spread of resistant strains of fungi with the capacity to cause serious disease.
Answered by Baroness Hayman of Ullock - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
This Government recognises the importance of carefully managing pesticide use, including fungicides, to protect the environment and human health and address the risks of resistance.
During the plant protection product approvals process, the Health and Safety Executive considers the potential for resistance development in the target pest organism. Where resistance is known or anticipated, limitations are placed on product use to mitigate resistance developing. Defra is also funding work by the Agriculture and Horticulture Development Board which provides farmers best practice to minimise the risk of resistance emerging.
Through the National Institute for Health and Care Research, the Department of Health and Social Care has provided over £12 million in funding over the last five years for research into fungal infections and tackling antifungal resistance. Defra has also co-funded a research programme for UK Research and Innovation on ‘Transdisciplinary research to tackle antimicrobial resistance’.
The UK Health Security Agency (UKHSA) is routinely monitoring threats from antifungal resistance. The National Mycology Reference Laboratory performs antifungal susceptibility testing of fungi from human infections from across the UK. UKHSA also monitors antifungal susceptibility testing data for fungal yeast pathogens isolated from blood samples from local microbiology laboratories in England. Trends are published annually.
Asked by: Laurence Turner (Labour - Birmingham Northfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he will make an assessment of the potential merits of measures in the Rhode Island Latex Gloves Safety Act 2024 to help prevent latex allergy harm in England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is working closely with a range of stakeholders across the Government, the National Health Service, voluntary organisations, and patient representative groups to consider how allergy care and support could be improved.
The Expert Advisory Group on Allergy met most recently on 3 December and continues to bring together key stakeholders to inform policymaking and identify priorities in relation to the holistic care of people with allergies.
In terms of the use of gloves for medical purposes, the NHS purchases examination and surgical gloves through NHS Supply Chain’s two national frameworks and, ultimately, it is the choice of NHS trusts which gloves they wish to procure. Regarding examination gloves, latex was once the most commonly used glove, but nitrile, latex-free, gloves are now the most common choice. There are also ‘specialist examination gloves’ available, which aim to provide a reduction in allergy irritation.
Surgical glove purchase decisions are generally more clinically lead, and the choice of manufacturer and glove is usually made by the surgeon or consultant. There are latex and latex-free options available via the Surgical Glove Framework.
Asked by: Tom Tugendhat (Conservative - Tonbridge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the reasons people with brain cancer are seeking treatment outside the UK, particularly in Germany, including the trend in the level of such treatments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Ensuring patients have access to the latest and most effective treatment options is a top priority for the Government.
That is why we are committed to supporting an innovative clinical research ecosystem in the United Kingdom so that patients in this country can be among the first to benefit as we make the National Health Service fit for the future.
The Government is supportive of Scott Arthur’s Private Members Bill on rare cancers, which will make it easier for clinical trials into rare cancers, such as brain cancers, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the NHS will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
Asked by: Jo White (Labour - Bassetlaw)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department will consider allowing families of vulnerable patients who are at highest risk, particularly those affected by transplants and kidney disease, access to NHS COVID vaccinations.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The JCVI has advised that population immunity to COVID-19 has increased due to a combination of naturally acquired immunity following recovery from infection and vaccine-derived immunity. COVID-19 is now a relatively mild disease for most people, though it can still be unpleasant, with rates of hospitalisation and death from COVID-19 having reduced significantly since COVID-19 first emerged.
The JCVI has also advised that as currently available COVID-19 vaccines provide limited protection against transmission and mild or asymptomatic disease, the focus of the programme is on offering vaccination to those most likely to directly benefit from vaccination. These are the oldest adults and individuals who are immunosuppressed.
The Government has accepted the JCVI advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps the evidence under regular review.